Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.09, delivering a surprise of 10%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Taysha Gene Therapies , which belongs to the Zacks Medical - Generic Drugs industry, posted revenues of $1.79 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 4.54%. This compares to year-ago revenues of $4.75 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Taysha Gene Thera
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
- Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
TSHA
Earnings
- 11/13/24 - Miss
TSHA
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- TSHA's page on the SEC website